CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-13 | Reider Paul Chief Commercial Officer | Shares withheld for taxes | −2,049 | $2.37 | $5K | 88,406 |
| 2023-11-22 | Lanfear Dennis M President & CEO | Option exercise | +41,000 | $1.42 | $58K | 695,853 |
| 2023-11-22 | Lanfear Dennis M President & CEO | Option exercise | +258,940 | $1.42 | $367K | 954,793 |
| 2023-11-22 | Lanfear Dennis M President & CEO | Sale | −223,100 | $2.02 | $450K | 731,693 |
| 2023-11-22 | Lanfear Dennis M President & CEO | Option exercise · Stock Option (Right to Buy) | −299,940 | 0 | ||
| 2023-07-18 | Ryan Michael Lee Director | Grant or award · Stock Option (Right to Buy) | +54,000 | 54,000 | ||
| 2023-06-13 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2023-06-13 | McMichael Bryan J See Remarks | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2023-06-13 | Stilwell McDavid Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2023-06-13 | Reider Paul Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2023-06-07 | Wahlstrom Mats Director | Grant or award · Stock Option (Right to Buy) | +38,250 | 38,250 | ||
| 2023-06-07 | STOLPER MARK Director | Grant or award · Stock Option (Right to Buy) | +38,250 | 38,250 | ||
| 2023-06-07 | Newcomer Lee Nisley Director | Grant or award · Stock Option (Right to Buy) | +38,250 | 38,250 | ||
| 2023-06-07 | TZOUMAKAS KIMBERLY JO Director | Grant or award · Stock Option (Right to Buy) | +38,250 | 38,250 | ||
| 2023-06-07 | O'Donnell-Tormey Jill Director | Grant or award · Stock Option (Right to Buy) | +38,250 | 38,250 | ||
| 2023-06-07 | Newton Charles W. Director | Grant or award · Stock Option (Right to Buy) | +38,250 | 38,250 | ||
| 2023-04-01 | Reider Paul Chief Commercial Officer | Shares withheld for taxes | −2,451 | $6.84 | $17K | 87,053 |
| 2023-04-01 | Stilwell McDavid Chief Financial Officer | Shares withheld for taxes | −3,457 | $6.84 | $24K | 102,252 |
| 2023-03-31 | Vexler Vladimir Chief Scientific Officer | Shares withheld for taxes | −16,278 | $6.84 | $111K | 116,361 |
| 2023-03-27 | McMichael Bryan J See Remarks | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 |
Page 6 of 39 · 768 trades